MUNICH—De Rigo Vision’s announcement on Monday that it is acquiring the eyewear division of The Rodenstock Group clears the way for Rodenstock to focus exclusively on its well-established spectacle lens business and further develop its medical and vision technology capabilities. The day after the announcement, the Munich-based company followed with its own statement in which it called the pending sale of its eyewear division “another major step on its transformational path to become a leading Med-Tech company in vision care.”

Rodenstock added that it will continue to invest in its R&D capabilities as well as product and service portfolio to best meet its customer’s needs, and “further strengthen its leadership position in biometric lenses.”
Rodenstock has been a global leader in prescription lenses for over 140 years, with a strong track record of innovative product development. With the introduction of its B.I.G. Vision (Biometric Intelligent Glasses) in 2020 and the launch of B.I.G. Norm technology in early 2022, Rodenstock reinforced its capabilities in developing advanced spectacle lens products.
“This strategic move serves our overarching goal of continuing Rodenstock’s growth as a Med-Tech company through innovation, commercial execution and digitalization,” said Rodenstock CEO Anders Hedegaard. “Rodenstock’s strong and growing pipeline of innovation and the ability to reinvent itself and thus drive the industry transformation is and has always been our biggest asset combined with the highest level of service for our customers and partners.”
Marcus Desimoni, CFO of Rodenstock, added, “The clear focus on our B.I.G. Vision glasses and our lens business will allow Rodenstock to continue its financial growth path.”